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Summary
Near-fatal asthma (NFA) is described as acute asthma associated with a respiratory arrest or 
arterial carbon dioxide tension greater than 50 mmHg, with or without altered consciousness, 
requiring mechanical ventilation. Risk factors for near fatal asthma have not been fully eluci-
dated. In 80-85% of all fatal events, a phenotype, characterized by eosinophilic inflammation 
associated with gradual deterioration occurring in patients with severe and poorly controlled 
asthma, has been identified. Regarding to the management, acute severe asthma remains a 
significant clinical problem, which needs to be identified to facilitate early and appropriate 
therapeutic interventions. The assessment relies on clinical signs, but additional information 
might be obtained from chest radiography or blood gas analysis. No investigation should delay 
the initiation of appropriate therapy. The goals of therapy are the maintenance of oxygenation, 
relief of airflow obstruction, reduction of airways edema and mucus plugging (with Increased 
use of medications such as beta-agonists via metered dose inhalers and nebulizers, oral and/or 
intravenous (other than by inhalation) corticosteroids and oral or intravenous theophylline) 
whereas supporting ventilation as clinically indicated. Of course, the emergency physician 
needs to consider the wide range of potential complications, as attention to these problems 
when managing severe acute asthma might significantly improve outcome. An understanding 
of the available agents and potential pitfalls in the management of NFA is mandatory for the 
emergency physician.
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Background
Asthma is a significant public health problem that is increas-
ing in prevalence and is associated with relevant morbidity and 
financial costs (1,2). There is suggestion that asthma-related 
deaths are decreasing, but a significant minority of individu-
als presents with severe asthma and have persisting daily symp-
toms, and exacerbations despite compliance with high doses of 
inhaled steroids and additional treatment. For this small part 
of the asthmatic population, the exacerbation can become fatal 
or near-fatal (1-10). These observations appear to be paradoxi-
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logical presence of inflammatory cells, mucus plugging, shed-
ding of airway epithelium, airway oedema and smooth muscle 
hypertrophy (6,14). Airway obstruction in severe asthma that 
does not respond to conventional therapy, may be caused by 
mucus plugging (6,14). Evidence for the management of mucus 
plugging in adult patients with severe near fatal asthma is sparse. 
Chia et al. describe a patient with fatal asthma who responded 
dramatically to DNase following bronchoscopy and lavage af-
ter failing other therapies in a case report, and believe that the 
combined use of rhDNase, bronchial toileting and aggressive 
physiotherapy, on top of mechanical ventilation strategies and 
intravenous bronchodilators, helped turn the corner (15).
More recently Serrano-Pariente et al. analysed 179 asthmatics 
patients admitted to the hospital for an episode of NFA. Three 
clusters of patients with NFA were identified: cluster 1, the larg-
est, including older patients with clinical and therapeutic criteria 
of severe asthma; cluster 2, with an high proportion of respira-
tory arrest, impaired consciousness level and mechanical ventila-
tion; and cluster 3, which included younger patients, character-
ized by an insufficient anti-inflammatory treatment and frequent 
sensitization to Alternaria alternata and soybean (7). 
Assessment
In a study of asthma patients admitted with a near-fatal episode, 
two-thirds of subsequent severe attacks or deaths occurred with-
in 1 year of the previous life-threatening admission (16). The 
immediate assessment of patients with asthma should include 
the degree of respiratory distress (ability to speak, respiratory 
rate, use of accessory muscles, air entry), degree of hypoxia (cya-
nosis, pulse oximetry, level of consciousness) and cardiovascular 
stability (arrhythmias, blood pressure). Accessory muscle use, 
wheeze and tachypnoea might diminish as the patient tires (17) 
(table 1). The clinical examination might be misleading; occa-
sionally asthmatics with poor perception of the severity of their 
asthma appear deceptively well, despite severe decrements in 
lung function. Although the assessment relies on clinical signs, 
additional information might be obtained from chest radiogra-
phy or blood gas analysis. No investigation should delay the ini-
tiation of appropriate therapy. On chest radiography, an episode 
of acute asthma is characterized by hyperinflation of the lungs. 
Physiologically abnormal distribution of ventilation, perfusion 
and altered gas exchange. Expiratory flow limitation with in-
complete expiration leads to hyperinflation of the lungs, adding 
to the elastic burden of the thorax. Passive elastic recoil is no 
longer sufficient to achieve effective expiration, and expiratory 
muscles are then actively involved in expiration (4,12). Progres-
sion of dynamic hyperinflation is associated with a higher intra-
thoracic pressure at the end of expiration (intrinsic Positive End 
Expiratory Pressure - iPEEP or auto-PEEP). Hyperinflation 
and higher intrathoracic pressures mean the respiratory muscles 
cal with the increasing knowledge of asthma pathogenesis and 
treatment that is currently available. Near-fatal asthma (NFA) 
is described as acute asthma associated with a respiratory ar-
rest or arterial carbon dioxide tension greater than 50 mmHg, 
with or without altered consciousness, requiring mechanical 
ventilation (8). Two distinctive phenotypes of NFA have been 
identified. The most common phenotype, responsible for 80-
85% of all fatal events, is characterized by eosinophilic inflam-
mation associated with gradual deterioration over days or weeks 
occurring in patients with severe and poorly controlled asthma, 
and is slow to respond to therapy. This phenotypic pattern is 
generally considered preventable. The second phenotype, with 
neutrophilic inflammation, has both rapid onset and response 
to therapy (4,7,11). 
Risk factors
Remodeling in asthma refers to structural changes in large and 
small airways, consisting of subepithelial fibrosis, increased vas-
cularity, increased airway smooth muscle mass, and goblet cell 
hyperplasia of proximal and distal airways. Remodeling was be-
lieved originally to be the cause of refractory asthma, that is, 
asthma that fails to respond to optimal treatment and is char-
acterized by persistent airflow limitation. A history of intensive 
care admission or mechanical ventilation is a well-documented 
indicator of subsequent NFA (12). Gelb et al. found that in 
NFA patients the sensitivity for the presence of moderate and/
or severe obstruction was 90%, the specificity was 61%, the 
positive predictive value was 41%, and the negative predictive 
value was 95%. The sensitivity for an abnormal loss of lung 
elastic recoil (i.e., less than the predicted normal mean _1.64 
SD) was 100%, the specificity was 79%, the positive predic-
tive value was 59%, and the negative predictive value 100% for 
NFA patients (13). Using TLC percent predicted as a surrogate 
for elastic recoil, the sensitivity for TLC of > 115% predicted 
was 70%, the specificity was 70%, the positive predictive value 
was 88%, and the negative predictive value was 41% for NFA 
patients (13). Using the ratio of FEV1 percent predicted to TLC 
percent predicted of < 0.70, the sensitivity was 90%, the speci-
ficity was 78%, the positive predictive value was 56%, and the 
negative predictive value was 96% for NFA patients (13). The 
unexpected loss of lung elastic recoil in patients with chronic 
persistent asthma, and its significant physiologic contribution 
to adverse clinical complications including NFA, are novel pro-
spective observations. This loss of lung elastic recoil was asso-
ciated with increasing age, duration of asthma, and severity of 
expiratory airflow limitation, using postbronchodilator FEV1 
percent predicted as the signal. Additionally, normal transdia-
phragmatic pressures, despite the presence of hyperinflation in 
patients with NFA, extend similar observations about asthmatic 
patients without NFA (6,14). Postmortem series show patho-
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ten used in the treatment of patients with acute asthma (18). 
Hypoxaemia in asthma results from ventilation / perfusion 
mismatching and is thus usually easily corrected with modest 
increases in the fraction of inspired oxygen (e.g. 1-3 L/min via 
a nasal cannula or mask). Uncontrolled oxygen has been pos-
tulated to correct the effects of hypoxaemia and to compensate 
for any trend towards a fall in arterial oxygen tension associated 
with b2-agonist therapy (19). Short-acting, inhaled b2-agonists 
are the drugs of choice for treating acute asthma. Their onset 
of action is rapid and their side-effects are well tolerated. Sal-
butamol, the most frequently used b2-agonist in ED around 
the world, has an onset of action of 5 min and a duration of 
action of 6 h. b2-agonists have been described as rescue ther-
apy for use in patients unresponsive to inhaled bronchodilator 
and systemic corticosteroid therapy, or when the inhaled route 
is not practical (20). The safety profile of short-acting-β2-ago-
nists has been questioned due to possible detrimental effects on 
asthma control. Recent evidence and meta-analysis suggest an 
increased risk for cardiovascular complications in patients us-
ing β2-agonists (21,22). There is evidence suggesting that the 
frequent use of these drugs might increase the risk of premature 
death. The hypothesis that β2-agonists can have fatal adverse 
effects was first demonstrated in the late 1960, when Inman and 
Adelstein reported a 30-700% increase, depending on age, in 
asthma death in patients using pressurized aerosol containing, 
most often, isoprenaline (23). The excess mortality was attribut-
ed to overdosing but β-agonists came into focus again in the 
1980, when more selective β2-agonists were introduced in me-
tered-dose inhaler. A dose-dependent risk of death from asth-
ma was reported, with increased up to 29-fold with the use of 
β2 agonists (24). Afterwards, large, randomised, double-blind 
start at greater stretch (hence less efficient, more fatiguable), and 
greater inspiratory effort is needed to commence flow into the 
lungs, which also increases work of breathing (4,12). Barotrau-
ma, which refers to the adverse effects of this increased intra-lung 
pressure on both the lung structure as well as that transmitted 
to the vascular structures, can result in bullae rupture, pneu-
mothorax and reduced venous return with hypotension. Blood 
gas analyses might reveal respiratory alkalosis, hypoxaemia and 
hypocarbia. Generally, asthma attacks are not characterized by 
marked arterial desaturations until very late in life-threatening 
episodes. Hypercarbia occurs in 10% of cases presenting to the 
ED (4,12). These patients have greater airway obstruction and 
respiratory rate than non-hypercapnic patients. A quiet chest 
on auscultation, inability to talk and cyanosis suggest the pres-
ence of hypercarbia. The finding of normocarbia in acute asth-
ma should also be viewed as a sign of impending respiratory 
failure that requires aggressive treatment, Patients who fail to 
respond to therapy (PEFR improved by less than 10-20%) or 
with persistent hypercapnia, tachypnoea (respiratory rate _30), 
altered mental status, arrhythmias or significant comorbidities 
should be referred to the ICU (4). The emergency physician also 
needs to consider the wide range of potential complications, as 
attention to these problems when managing severe acute asthma 
might significantly improve outcome (table 2).
Therapy
The goals of therapy are the maintenance of oxygenation, relief 
of airflow obstruction, reduction of airway o edema and mucus 
plugging whereas supporting ventilation as clinically indicated. 
High-flow oxygen has been assumed to be harmless, and is of-
Table 1 - Markers of severe asthma.
Inability to speak in full sentences
FEV1 < 40%, predicted or PEF < 40% of best or predicted 
(< 25% in life-threatening asthma)
Oxygen saturations < 90-92%
PaO2 < 60 mmHg - PaCO2 > 45 mmHg
Use of accessory muscles or tracheal tugging
Pulsus paradoxus (> 15 mmHg decrease with inspiration). 
With severe muscle fatigue might be absent
Quiet chest on auscultation
Patient seated upright and unable to lie supine
Cyanosis and sweating
Confusion or decreased level of consciousness - Hypotension 
or bradicardia
Table 2 - Asthma complications.
Pneumothorax
Pneumomediastinum - Pneumopericardium
Pulmonary interstitial emphysema
Pneumoretroperitoneum
Cardiac arrhythmias
Myocardial ischaemia or infarction
Mucus plugging - Atelectasis - Pneumonia
Electrolyte disturbances (hypokalaemia, hypomagnesaemia, 
hypophosphataemia)
Lactic acidosis - Hyperglycaemia
Theophylline toxicity
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appear to offer a therapeutic advantage, and because the risk of 
myopathy is significant, especially in the mechanically ventilat-
ed patients, the concomitant use of systemic corticosteroids and 
paralytic agents should be avoided if at all possible. Importantly 
oral and i.v. routes of corticosteroid administration are equally 
efficacious with respect to rate of resolution of airflow limita-
tion (32). The parenteral route is required in patients unable 
to take oral medication (intubated) or if absorption might be 
compromised (e.g. vomiting). There is some suggestion that for 
patients with severe symptoms, i.v. corticosteroid therapy might 
have an early effect (within 1-6 h) by reversing b2-receptor 
downregulation seen in chronic b2-agonist use (33). The use of 
i.v. aminophylline was associated with a higher incidence of ad-
verse effects compared with standard care alone (34). Whether 
aminophylline has a place as an additional therapy after treat-
ment with established medications such as inhaled b-agonists, 
systemic corticosteroids and i.v. magnesium remains uncertain. 
At the current time routine use of aminophylline in severe asth-
ma cannot be recommended. Magnesium might be effective in 
acute asthma through a variety of mechanisms. This cation is an 
important cofactor in many intracellular enzymatic reactions. 
Magnesium has been shown to relax smooth muscle and might 
be involved with inhibition of smooth-muscle contraction. As 
an explanation for the effects of magnesium in acute asthma this 
is perhaps overly simplistic. Magnesium is involved in acetyl-
choline and histamine release from cholinergic nerve terminals 
and mast cells, respectively. Furthermore, the ability of magne-
sium to block the calcium-ion influx into the bronchial smooth 
muscle might have therapeutic benefit in severe acute asthma 
(35). A single dose of i.v. MgSO4 administered to patients with 
severe acute asthma has been shown to be effective. A multi-
centre trial demonstrated that 2 g of i.v. magnesium sulphate 
administered as an adjunct to standard therapy, improved pul-
monary function in patients presenting to the ED with severe 
asthma. i.v. (36). Montelukast in addition to standard therapy 
produces rapid benefit and is well tolerated in adults who have 
acute asthma. Patients with severe bronchospasm requiring me-
chanical ventilation and not responding to conventional bron-
chodilator therapy might benefit from an inhaled volatile anaes-
thetic agent with bronchodilating properties such as halothane, 
enflurane or isoflurane (37-41). Use of these agents might result 
in hypotension and cardiac dysrhythmias, especially in hypoxic 
patients. Administration is complex and requires either an an-
aesthetic machine or alternative heat moisture connector device. 
For practical reasons this therapy is better reserved for use in 
the ICU. Despite appropriate therapy, there continues to be a 
small group of patients who deteriorate or those who present 
in extremis and require mechanical ventilation. The rate of in-
tubation in patients with acute severe asthma is low at 3-8% 
(42). Surprisingly, only a few reports have described the use of 
trials have been performed to test the hypothesis that the use 
of LABAs in asthmatic patients is associated with an increased 
risk of death (25). At present, patients with asthma should be 
initiated and maintained on sufficiently high doses of inhaled 
corticosteroids and only patients whose asthma cannot be con-
trolled should receive additional β2-agonists on a regular basis 
in addition, LABA should be withdrawn from patients who do 
not profit from their use (1). The need for reliever medication, 
such as the inhaled short-acting β2-agonists (SABA) albuterol, 
along with daytime symptoms, nighttime waking and activity 
limitations, is used to assess symptom control in asthma and to 
estimate the risk of future exacerbations (1).
The inclusion of reliever inhaler use in assessment of asthma 
control in adults, used on evidence that overuse of SABA med-
ication is associated with poor symptom control, increased risk 
of exacerbations and death from asthma (26).
Adrenaline has been used both as a nebulized solution and intra-
venously. There are theoretical advantages to the preferential use 
of i.v. adrenaline as opposed to pure b2-agonists in acute severe 
asthma. Although bronchoconstriction is the major pathology 
in asthma, airway oedema might also make a significant contri-
bution. Both the a-agonist and β-agonist effects of adrenaline 
might be beneficial, with the a-effect decreasing oedema and 
the b-effect responsible for bronchodilation. Anticholinergics 
agents block muscarinic receptors in airway smooth muscles, 
inhibit vagal cholinergic tone and result in bronchodilation. 
Ipratropium bromide has a mild additional bronchodilating ef-
fect when added to b-agonists, that might only be significant in 
severe asthma (20). Because anticholinergic agents and b2-ago-
nists exert effects by different mechanisms, affect different-sized 
airways and have different pharmacodynamic and pharmaco-
kinetic properties, the combined use of them is rational and 
is likely to result in improved bronchodilation. Corticosteroids 
have been shown to improve asthma symptoms by reducing 
airway inflammation, airway reactivity and decrease airway 
secretions. In addition to their anti-inflammatory effect, ste-
roids increase the number and sensitivity of b-receptors on the 
bronchial smooth muscle (28,29). Objective improvements in 
airflow obstruction have usually not been demonstrated during 
the first 6-12 h of treatment with corticosteroids in acute asth-
ma (30). Corticosteroids are recommended for most patients 
in the ED, particularly in those who do not respond complete-
ly to initial b2-agonist therapy. Corticosteroid administration 
reduces admission rates, decreases relapse rates and might also 
reduce the number of cases of fatal asthma. Because benefits 
from corticosteroid treatment are not usually seen for 6-24 h af-
ter administration, therapy should be instituted early. Low dose 
corticosteroids (_80 mg/day of methylprednisolone or _400 
mg/day of hydrocortisone) appear to be adequate in the initial 
management of adult patients (31). Higher steroid doses do not 
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than morphine, but on rare occasions can induce chest wall ri-
gidity with rapid bolus dosing (47). Ongoing paralysis might 
initially be required to facilitate ventilation; however, because 
of the significant risk of critical illness polyneuromyopathy (es-
pecially given the combination with steroids), neuromuscular 
blockade should be withdrawn as soon as possible. The inci-
dence of myopathy in asthmatics on long-term nondepolariz-
ing neuromuscular blocking agents has been reported as high as 
30% (48). The mode of ventilation might be a crucial factor for 
a successful outcome of NFA. Mechanical ventilation is often 
difficult because the obstructive defect might result in dynamic 
hyperinflation. This might then lead to barotrauma, volutrau-
ma or catastrophic haemodynamic compromise secondary to 
impairment of venous return. Regardless of the mode of venti-
lation selected, the goals of mechanical ventilation are to main-
tain adequate oxygenation, minimize dynamic hyperinflation, 
avoid barotrauma and accept some degree of hypercapnia until 
bronchodilators and steroids improve airflow. Outcome is im-
proved in mechanically ventilated asthmatics by limiting airway 
pressure using a low respiratory rate and tidal volume, whereas 
permitting a moderate degree of hypercarbia and respiratory ac-
idosis (49). Hypercarbia has not been found to be detrimental, 
except in patients with severe myocardial depression. Moderate 
degrees of hypercarbia with an associated acidosis (pH 7.15-
7.2) are generally well tolerated. To prolong the expiratory time 
and allow adequate time for expiration, the breath rate can be 
reduced, or inspiratory time decreased thereby extending the 
inspiratory to expiratory (I:E) ratio to much greater than 1:2. 
Expiration should ideally be observed both clinically and on the 
ventilator graphics to be complete before the next breath is de-
livered. Pressure control ventilation might not be an ideal mode 
of ventilation for patients with NFA, as frequent fluctuations 
in airway resistance lead to variable tidal volumes and a risk of 
significant hypoventilation. The use of extrinsic PEEP remains 
controversial, in mechanically ventilated paralysed patients, and 
Tuxen found it to be of no benefit at low levels and detrimental 
at high levels, because the decrease in gas trapping was replaced 
by a rise in functional residual capacity (50). It should be noted 
that very large tidal volumes were used in the present study. 
Extrinsic PEEP might prevent airway collapse by splinting the 
airways open (51); however, as a general rule, extrinsic PEEP 
should not exceed intrinsic PEEP, and ongoing clinical assess-
ment for the presence of gas trapping and magnitude of FRC are 
mandatory. Ensuring adequate humidification of inspired gas is 
particularly important in the ventilated asthmatic, to prevent 
further thickening of secretions and drying of airway mucosa 
that might stimulate further bronchospasm. Finally, it should be 
noted that mechanical ventilation might compromise delivery 
of aerosolized bronchodilators. Drug delivery might vary from 
0% to 42% in ventilated patients, and it is therefore important 
non-invasive ventilation (NIV) in patients with acute severe 
asthma (43,44). The positive pressures employed in the studies 
to date are generally less than 15 cm H
2
O, and whether CPAP 
or BiPAP is the optimal approach remains unknown. Although 
there are some similarities between asthma and chronic obstruc-
tive pulmonary disease, in asthma CO
2
 retention occurs late in 
the exacerbation and by that time the patient is often exhaust-
ed and has difficulty tolerating the NIV mask. Furthermore, 
patients with severe acute asthma are usually tachypnoeic and 
might struggle to coordinate their breathing with that of the 
machine and therefore find BiPAP uncomfortable. Mucous pro-
duction is a feature of severe acute asthma and NIV can exacer-
bate sputum retention, and it is important that this is borne in 
mind when implementing NIV. A Cochrane review performed 
in 2005 concluded there are promising results in favour of the 
use of NPPV in severe acute asthma; however, the regular use 
of NPPV in status asthmaticus still remains controversial. Until 
large randomized controlled trials are completed, this therapy 
should be restricted, and routine clinical use cannot be recom-
mended (45).
Invasive ventilation
Deteriorating consciousness, severe exhaustion and cardiopul-
monary arrest are absolute indications for intubation and me-
chanical ventilation. Severe hypercapnia, acidosis and fatigue 
might not warrant immediate intubation, but rather aggressive 
and continuous bronchodilator therapy. Intubation and me-
chanical ventilation in the asthmatic should not be embarked 
upon lightly. Once it is apparent that invasive ventilation is re-
quired, experienced help should be sought. The optimal means 
of intubation is usually direct laryngoscopy, following rapid se-
quence induction. The best agents to use are those most familiar 
to the operator. Induction might effectively be achieved with 
propofol or thiopentone; however careful dosage adjustment is 
required for potential haemodynamic compromise. The asth-
matic patient is often volume-depleted, with induction result-
ing in both loss of sympathomimetic tone and drug-induced 
vasodilation. Additional to this, the development of intrinsic 
PEEP with an inappropriate ventilation strategy might rapidly 
result in catastrophic circulatory collapse. In this regard ket-
amine with its sympathomimetic and bronchodilating prop-
erties has been advocated by many as the induction agent of 
choice (46). Inhalational volatile induction is attractive given 
the bronchodilating properties of these agents, and it might 
obviate the need for paralysis. It however requires specialized 
anaesthetic skills and equipment to be available in the emer-
gency room, as transfer of such critically ill patients would be 
ill advised. Following induction, maintenance with fentanyl 
and midazolam is appropriate. Fentanyl is the opiate of choice 
because it inhibits airway reflexes, causes less histamine release 
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Table 3 - Initial ventilator settings in paralysed asthmatic patients.
FiO2 1.0, then titrate to keep SpO2 > 94%
Tidal volume 5-6 mL/kg
Ventilator rate 6-8 breaths/min
Long expiratory time (I:E ratio > 1:2)
Minimal PEEP _5 cmH2O
Limit peak inspiratory pressure to < 40 cmH2O
Target plateau pressure < 20 cmH2O
Ensure effective humidification
Conclusion
Acute severe asthma remains a significant clinical problem, 
which needs to be identified to facilitate early and appropri-
ate therapeutic interventions. In this regard the identification 
of patients with a specific NFA phenotype could be helpful to 
prevent future severe asthma exacerbations. An understanding 
of the available agents and potential pitfalls in the management 
of NFA is mandatory for the emergency physician.
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